Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
43%
Alpelisib
7%
Anticancer Drug
41%
Anticarcinogen
17%
Bortezomib
24%
Breast Cancer
31%
Cabazitaxel
10%
Chemotherapy
27%
Cisplatin
10%
Clinical Trial
100%
Combination Therapy
13%
Coronavirinae
7%
Cytotoxic Chemotherapy
8%
Dedifferentiated Liposarcoma
7%
Diffuse Large B Cell Lymphoma
7%
Disease Exacerbation
18%
Diseases
28%
Drug Administration
7%
Emphysema
7%
Erlotinib
9%
Fibronectin
7%
Immunotherapy
40%
Lymph Vessel Metastasis
7%
Malignant Neoplasm
71%
Malignant Peripheral Nerve Sheath Tumor
7%
Maximum Tolerated Dose
70%
Metastatic Colorectal Cancer
7%
Metastatic Uvea Melanoma
15%
Metformin
7%
Neoplasm
15%
Neuropathy
10%
Overall Survival
12%
Pexidartinib
7%
Phase I Trials
7%
Phase II Trials
7%
Placebo
7%
Premature Labor
7%
Progression Free Survival
30%
Propranolol
7%
Rapamycin
7%
Rituximab
7%
Ruxolitinib
7%
Sitravatinib
7%
Sotrastaurin
7%
Taxane
8%
Tolerability
29%
Toxicity
7%
Transitional Cell Carcinoma
7%
Triple Negative Breast Cancer
8%
Venous Thromboembolism
7%
Medicine and Dentistry
Adverse Event
20%
Anticancer Drug
22%
Anticarcinogen
7%
Breast Cancer
48%
Breast Tumor
11%
Cerebrospinal Fluid
7%
Checklist
7%
Cisplatin
12%
Clinical Trial
61%
Clinician
8%
COVID-19
22%
Cytokeratin
7%
Disease Exacerbation
8%
Diseases
27%
DLCO
7%
Drug Prescription
11%
Emphysema
14%
Exercise Test
7%
Hormone Therapy
8%
Immunotherapy
12%
Intraoperative Radiation Therapy
7%
Lumpectomy
7%
Lung
17%
Lymph Node Metastasis
8%
Lymphovascular Invasion
7%
Malignant Neoplasm
44%
Metastatic Breast Cancer
8%
Metastatic Carcinoma
12%
Neoadjuvant Chemotherapy
9%
Neoplasm
17%
Odds Ratio
9%
Oncology
13%
Overall Survival
26%
Patient-Reported Outcome
15%
Pneumonectomy
15%
Progression Free Survival
10%
Pulmonary Fibrosis
7%
Quality of Life
10%
Radiation Therapy
12%
Recurrent Disease
8%
Reproducibility
12%
Rituximab
7%
Six Minute Walk Test
8%
Surgeon
11%
Surgery
12%
Survival Rate
8%
Targeted Therapy
19%
Triple Negative Breast Cancer
11%
Tumor Recurrence
7%
Venous Thromboembolism
7%
Nursing and Health Professions
Adverse Event
16%
Artificial Tear
7%
Breast Cancer
7%
Cancer Therapy
8%
Central Corneal Thickness
7%
Chemotherapy-Induced Peripheral Neuropathy
5%
Combination Therapy
7%
Compression Therapy
7%
Confidence Interval
9%
Cryotherapy
7%
Diseases
5%
Dose Calculation
10%
Drug Dose
5%
Emphysema
5%
Fibronectin
7%
Functional Status
5%
Interstitial Pneumonia
5%
Lung Fibrosis
7%
Lung Resection
7%
Malignant Neoplasm
7%
Maximum Tolerated Dose
5%
Metastatic Breast Cancer
7%
National Health Organization
10%
Neuropathy
7%
Nomenclature
7%
Oncologist
5%
Pachymetry
7%
Personalized Care
5%
Placebo
7%
Practice Guideline
5%
Premature Labor
7%
Radiologist
7%
Randomization
5%
Reflectometry
7%
Scoring System
5%
Treatment Outcome
5%
X-Ray Computed Tomography
5%
